Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Archin, Nancie M ^a   Cheema, Manzoor ^a   Parker, Daniel ^a   Wiegand, Ann ^b   Bosch, Ronald J ^c   Coffin, John M ^b   Eron, Joseph ^a   Cohen, Myron ^a   Margolis, David M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DEPAKOTE ER; ENFUVIRTIDE; RALTEGRAVIR; UNCLASSIFIED DRUG; VALPROIC ACID; 2 PYRROLIDONE DERIVATIVE; ENZYME INHIBITOR; GLYCOPROTEIN GP 41; HISTONE DEACETYLASE INHIBITOR; PEPTIDE FRAGMENT; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE REACTION; MALE; OUTCOME ASSESSMENT; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; BLOOD; CD4 CD8 RATIO; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME; VALPROIC ACID; VIREMIA;

EID: 77949592502     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009390     Document Type: Article

References (20)

1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The Challenge of a Cure for HIV Infection. Science 2009 323: 1304-1307.
2. Quivy V, Adam E, Collette Y, Demonte D, Chariot A, et al. (2002) Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 76: 11091-11103.
3. Ylisastigui L, Archin N, Lehrman G, Bosch RJ, Margolis DM (2004) Coaxing human immunodeficiency virus type 1 from resting CD4+ T cells: can the reservoir of HIV be purged? AIDS 18: 1101-1108.
4. Bowman MC, Archin NM, Margolis DM (2009) Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med 11: e6.
5. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, et al. (2005) Depletion of latent HIV infection in vivo. Lancet 36: 549-555.
6. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, et al. (2007) Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. Journal of Infectious Diseases 195: 833-836.
7. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, et al. (2008) Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 22: 1125-1129.
8. Archin NA, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, et al. (2008) Standard ART and Valproic Acid Have Limited Impact on the Persistence of HIV Infection in Resting CD4+ T Cells. AIDS 22: 1131-1135.
9. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, et al. (2003) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41: 4531-4536.
10. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, et al. (2005) Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293: 817-829.
11. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893-900.
12. th Annual Conference on Retroviruses and Opportunistic Infections, Montreal PQ; abstr. 424.
13. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106: 9403-8.
14. th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa.
15. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-12.
16. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284: 6782-9.
17. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, et al. (2009) Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 23: 1799-806.
18. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, et al. (2009) A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 83: 4749-56.
19. Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J (2009) Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 7: 798-812.
20. Colin L, Van Lint C (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6: 111.